Journal Of Medicinal Chemistry SCIE

国际简称：J. Med. Chem. 参考译名：药物化学杂志

主要研究方向：医学-医药化学非预警期刊审稿周期：约2.1个月

《药物化学杂志》(Journal Of Medicinal Chemistry)是一本由American Chemical Society出版的以医学-医药化学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

1区中科院分区
Q1 JCR分区
922 年发文量
6.8 IF影响因子
开放是否OA
240 H-index
1959 创刊年份
Biweekly 出版周期
English 出版语言

The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

Some specific areas that are appropriate include the following:

* Design, synthesis, and biological evaluation of novel biologically active compounds, diagnostic agents, or labeled ligands employed as pharmacological tools.

* Molecular modifications of reported series that lead to a significantly improved understanding of their structure-activity relationships (SAR). Routine extensions of existing series that do not utilize novel chemical or biological approaches or do not add significantly to a basic understanding of the SAR of the series will normally not be accepted for publication.

*Structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with the aim of investigating molecular recognition processes in the action of biologically active compounds.

* Molecular biological studies (e.g., site-directed mutagenesis) of macromolecular targets that lead to an improved understanding of molecular recognition.

*Computational studies that provide fresh insight into the SAR of compound series that are of current general interest or analysis of other available data that subsequently advance medicinal chemistry knowledge.

* Substantially novel computational chemistry methods with demonstrated value for the identification, optimization, or target interaction analysis of bioactive molecules.

* Effect of molecular structure on the distribution, pharmacokinetics, and metabolic transformation of biologically active compounds. This may include design, synthesis, and evaluation of novel types of prodrugs.

* Novel methodology with broad application to medicinal chemistry, but only if the methods have been tested on relevant molecules.

[ 查看全部 ]

投稿咨询加急咨询

Journal Of Medicinal Chemistry期刊信息

ISSN：0022-2623
出版语言：English
是否OA：开放
E-ISSN：1520-4804
出版地区：UNITED STATES
是否预警：否
出版商：American Chemical Society
出版周期：Biweekly
创刊时间：1959
开源占比：0.099
Gold OA文章占比：13.77%
OA被引用占比：0.0691...
出版国人文章占比：0.14
出版撤稿占比：0.0011...
研究类文章占比：98.81%

Journal Of Medicinal Chemistry CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

12.8

1.986

1.594

学科类别	分区	排名	百分位
大类：Pharmacology, Toxicology and Pharmaceutics 小类：Drug Discovery	Q1	13 / 157	92%
大类：Pharmacology, Toxicology and Pharmaceutics 小类：Molecular Medicine	Q1	24 / 178	86%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Journal Of Medicinal Chemistry中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	CHEMISTRY, MEDICINAL 药物化学	1区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	CHEMISTRY, MEDICINAL 药物化学	1区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	CHEMISTRY, MEDICINAL 药物化学	1区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	2区	CHEMISTRY, MEDICINAL 药物化学	1区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	CHEMISTRY, MEDICINAL 药物化学	1区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	CHEMISTRY, MEDICINAL 药物化学	1区

Journal Of Medicinal Chemistry JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：CHEMISTRY, MEDICINAL	SCIE	Q1	4 / 72	95.1%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：CHEMISTRY, MEDICINAL	SCIE	Q1	1 / 72	99.31%

Journal Of Medicinal Chemistry历年数据统计

影响因子

中科院分区

Journal Of Medicinal Chemistry中国学者发文选摘

1、Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small- cell Lung Cancer
Author: Pei, Junping; Wang, Guan; Wang, Aoxue; Wu, Chengyong; Pan, Xiaoli; Shuai, Wen; Bu, Faqian; Zhu, Yumeng; Wang, Yuxi; Ouyang, Liang; Li, Weimin

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00027
2、Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Author: Zhu, Chenyu; Ze, Shuyin; Zhou, Ronghui; Yang, Xinyu; Wang, Haojie; Chai, Xiaolei; Fang, Meimiao; Liu, Mingyao; Wang, Yonghui; Lu, Weiqiang; Xie, Qiong

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4734-4754. DOI: 10.1021/acs.jmedchem.2c018604734J
3、Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway
Author: Zhang, Xinqi; Han, Qianyu; Hou, Ruilin; Xu, Lijuan; Zhang, Wannian; Xing, Chengguo; Xue, Lei; Zhuang, Chunlin

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 5261-5278. DOI: 10.1021/acs.jmedchem.3c00197
4、Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives
Author: Xie, Yuting; Yue, Lin; Shi, Yaojie; Su, Xingping; Gan, Cailing; Liu, Hongyao; Xue, Taixiong; Ye, Tinghong

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4342-4360. DOI: 10.1021/acs.jmedchem.2c01753
5、Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling
Author: Luo, Guangmei; Wang, Bingrui; Hou, Qiangqiang; Wu, Xiaoxing

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4324-4341. DOI: 10.1021/acs.jmedchem.2c01729
6、Unsymmetrical Phosphodiesters as GPR84 Antagonists with High Blood Exposure for the Treatment of Lung Inflammation
Author: Li, Shao-Xian; Wang, Si-Wei; Chen, Lin-Hai; Zhang, Qing; Lu, Dan; Chen, Jing; Fang, You-Chen; Gu, Min; Xie, Xin; Nan, Fa-Jun

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 8, pp. 5820-5838. DOI: 10.1021/acs.jmedchem.3c00053
7、Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1
Author: Gallego, Rebecca A.; Bernier, Louise; Chen, Hui; Cho-Schultz, Sujin; Chung, Loanne; Collins, Michael; Del Bel, Matthew; Elleraas, Jeff; Jones, Cinthia Costa; Cronin, Ciaran N.; Edwards, Martin; Fang, Xu; Fisher, Timothy; He, Mingying; Hoffman, Jacqui; Huo, Ruiduan; Jalaie, Mehran; Johnson, Eric; Johnson, Ted W.; Kania, Robert S.; Kraus, Manfred; Lafontaine, Jennifer; Le, Phuong; Liu, Tongnan; Maestre, Michael; Matthews, Jean; McTigue, Michele; Miller, Nichol; Mu, Qiming; Qin, Xulong; Ren, Shijian; Richardson, Paul; Rohner, Allison; Sach, Neal; Shao, Li; Smith, Graham; Su, Ruirui; Sun, Bin; Timofeevski, Sergei; Tran, Phuong; Wang, Shuiwang; Wang, Wei; Zhou, Ru; Zhu, Jinjiang; Nair, Sajiv K.

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4888-4909. DOI: 10.1021/acs.jmedchem.2c02038
8、Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers
Author: Qiu, Qianqian; Chi, Fanglian; Zhou, Daoguang; Xie, Zhancheng; Liu, Yunxiao; Wu, Hanyu; Yin, Ziyu; Shi, Wei; Qian, Hai

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00036